Posts

KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.

KEYNOTE-158 pembrolizumab in previously treated advanced cervical cancer

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

 

  • On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.
Ribociclib FDA label updated to include pre- and perimenopausal women